gefitinib has been researched along with ggti 298 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (ggti 298) | Trials (ggti 298) | Recent Studies (post-2010) (ggti 298) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 71 | 0 | 17 |
| Protein | Taxonomy | gefitinib (IC50) | ggti 298 (IC50) |
|---|---|---|---|
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.054 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 0.054 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, F; Dai, XY; Gong, QY; Liu, BS; Nie, YZ; Tang, QL; Xia, HW; Xu, HJ | 1 |
1 other study(ies) available for gefitinib and ggti 298
| Article | Year |
|---|---|
Geranylgeranyl transferase 1 inhibitor GGTI‑298 enhances the anticancer effect of gefitinib.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Phosphorylation; Proto-Oncogene Proteins c-akt; rhoA GTP-Binding Protein; Signal Transduction | 2018 |